-
公开(公告)号：EP3180328A1
公开(公告)日：2017-06-21
申请号：EP15753856.2
申请日：2015-08-14
发明人： CARROLL, David , SRAN, Arvinder , SINGH, Rajinder , HUANG, Jianing , TSVETKOV, Lyuben , ISSAKANI, Sarkiz , PAYAN, Donald , SHAW, Simon
IPC分类号： C07D401/14 , C07D215/40 , C07D401/04 , C07D401/12 , C07D405/04 , C07D409/04 , A61K31/4706 , A61K31/496 , A61K31/5377 , A61P35/00
摘要： Disclosed are sulfonamidoquinoline compounds, as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein R1, R2, R3 and R4 are as described herein. In certain embodiments, a compound disclosed herein inhibits ubiquitination, and can be used to treat disease by blocking the degradation of tumor suppressors.
摘要翻译： 公开了磺酰胺基喹啉化合物，以及药物组合物和使用方法。 一个实施方案是具有结构和其药学上可接受的盐，前药和N-氧化物（及其溶剂化物和水合物）的化合物，其中R 1，R 2，R 3和R 4如本文所述。 在某些实施方案中，本文公开的化合物抑制泛素化，并且可用于通过阻断肿瘤抑制剂的降解来治疗疾病。
-
公开(公告)号：EP3140301A1
公开(公告)日：2017-03-15
申请号：EP15726218.9
申请日：2015-05-08
申请人： Orion Corporation
发明人： PRUSIS, Peteris , HÖGLUND, Iisa , TÖRMAKANGAS, Olli , HIETANEN, Ari , ARVELA, Riina , VESALAINEN, Anniina , HEIKKINEN, Terhi
IPC分类号： C07D405/04 , C07D405/06 , C07D239/96 , A61K31/517 , A61P25/00
CPC分类号： C07D239/96 , A61K49/0052 , C07D405/04 , C07D405/06 , C07D491/056 , C07D498/06
摘要： wherein R1 through R8 are as defined in the claims, exhibit a positive allosteric GABAB modulator effect and are thus useful as positive allosteric modulators of the GABAB receptor.
摘要翻译： 其中R1至R8如权利要求中所定义，表现出正变构GABAB调节作用，因此可用作GABA B受体的正变构调节剂。
-
3.发明授权
公开(公告)号：EP2079694B1
公开(公告)日：2017-03-01
申请号：EP07855342.7
申请日：2007-12-21
发明人： SINGH, Rajinder , YU, Jiaxin , HONG, Hui , THOTA, Sambaiah , XU, Xiang , DARWISH, Ihab
IPC分类号： C07D211/58 , C07D211/96 , C07D401/14 , C07D405/14 , A61K31/4545 , A61P3/10 , A61P9/00 , C07D409/14
CPC分类号： C07D401/12 , C07D211/58 , C07D211/96 , C07D401/14 , C07D405/14 , C07D409/14
-
4.发明公开ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING 审中-公开ANALOGA VON FEXARAMIN UND VERFAHREN ZUR HERSTELLUNG UND VERWENDUNG
公开(公告)号：EP3116851A1
公开(公告)日：2017-01-18
申请号：EP15760948.8
申请日：2015-03-13
发明人： EVANS, Ronald, M. , DOWNES, Michael , ATKINS, Annette , FANG, Sungsoon , SUH, Jae, Myoung , BAIGA, Thomas, J. , YU, Ruth, T. , KEANA, John F.W.
IPC分类号： C07C229/44 , C07D231/56 , C07D235/06 , C07D263/56 , C07D265/36 , C07D275/04 , C07D277/64 , C07D279/16 , C07D309/30 , C07D319/18 , C07D339/08 , A61K31/16 , A61K31/21 , A61K31/33 , A61P1/04 , A61P1/16 , A61P29/00 , A61P31/00
CPC分类号： C07D279/16 , A61K31/216 , A61K31/416 , A61K45/06 , C07C233/63 , C07C2601/14 , C07C2602/42 , C07D231/56 , C07D235/06 , C07D263/56 , C07D265/36 , C07D275/04 , C07D277/64 , C07D309/30 , C07D319/18 , C07D339/08 , A61K2300/00
摘要： Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (
e.g. , via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (
e.g. , via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.摘要翻译： 本文公开了具有其制备方法的配方实施方案的新型化合物和包含它们的组合物。 还公开了治疗或预防受试者代谢紊乱的方法的实施方案，包括向受试者（例如经由胃肠道）施用治疗有效量的一种或多种所公开的化合物，由此激活受试者中的FXR受体 肠，以及治疗或预防受试者的代谢紊乱。 另外公开了治疗或预防受试者肠道区域炎症的方法的实施方案，其包括向受试者（例如经由胃肠道）施用治疗有效量的一种或多种所公开的化合物，由此激活FXR受体 在肠内，从而治疗或预防受试者的肠道区域的炎症。
-
公开(公告)号：EP1675474B2
公开(公告)日：2016-12-07
申请号：EP04763629.5
申请日：2004-07-29
发明人： ISELE, Ute
IPC分类号： A23K50/42 , A23K40/00 , A23K20/163 , A23K20/116 , A61K9/00
CPC分类号： A61K9/0056 , A23K20/163 , A23K20/195 , A23K40/20 , A23K50/42 , A61K31/17 , A61K31/365 , A61K31/4985 , A61K38/13 , A61K47/10 , A61K47/36
-
公开(公告)号：EP3078658A1
公开(公告)日：2016-10-12
申请号：EP16167779.4
申请日：2009-12-21
申请人： ChemoCentryx, Inc.
发明人： FAN, Pingchen , GREENMAN, Kevin Lloyd , LELETI, Manmohan Reddy , LI, Yandong , POWERS, Jay , TANAKA, Hiroko , YANG, Ju , ZENG, Yibin
IPC分类号： C07D211/60 , C07D401/06 , C07D401/10 , C07D401/14 , C07D405/10 , C07D413/12 , A61P37/06 , A61K31/445 , A61K31/451 , A61K31/4545 , A61K31/5377
CPC分类号： A61K31/5377 , A61K31/445 , A61K31/451 , A61K31/454 , A61K31/4545 , C07D211/60 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/10 , C07D413/12 , C07D413/14
摘要： A process for preparing a compound of formula (ii),
comprising
(a) treating a compound of formula (i) with H 2 and a platinum oxide catalyst under reducing conditions; and
(b) subjecting the product of step (a) to resolution with di-toluoyl-L-tartaric acid to provide compound (ii) in about 97% enantiomeric excess.摘要翻译： （ii）的化合物的制备方法，其包括（a）在还原条件下用H 2和氧化铂催化剂处理式（i）的化合物; 和（b）用二对甲苯酰-L-酒石酸处理步骤（a）的产物以提供约97％对映体过量的化合物（ii）。
-
公开(公告)号：EP3074350A1
公开(公告)日：2016-10-05
申请号：EP14863272.2
申请日：2014-11-20
申请人： University Of Idaho
发明人： MOLLER, Gregory , STRAWN, Daniel
IPC分类号： C02F9/08 , C02F1/28 , C02F1/56 , C02F1/78 , C02F101/10 , C02F103/06
CPC分类号： C02F9/00 , B01J20/20 , B01J20/3204 , B01J20/3236 , B01J2220/4812 , C02F1/283 , C02F1/52 , C02F1/722 , C02F1/78 , C02F2101/105 , C02F2101/30 , C02F2101/305 , C02F2103/001 , C05F11/02 , Y02E50/343 , Y02P20/136 , Y02W30/47
摘要： Disclosed herein are embodiments of a system for treating water. The system comprises a biochar inlet, and optionally a metal salt inlet, ozone inlet, organic carbon compound inlet or any combination thereof. The biochar may be produced by biomass pyrolysis and the pyrolysis may be coupled to energy generation. The system also comprises a filtration device, such as a reactive filtration device. The system produces a treated water stream and a reject stream, which may be further separated into a recycled water stream and a solid product. The solid product may be suitable as a soil amendment for application to agricultural land, or for recycling. A method for using the system to treat water also is disclosed.
-
8.发明授权
公开(公告)号：EP1497307B1
公开(公告)日：2016-08-03
申请号：EP03726193.0
申请日：2003-04-01
CPC分类号： G01N33/56905 , A61K39/00 , A61K39/015 , C07K14/445 , C07K16/205 , C12N15/67 , C12P21/02 , G01N2333/445 , G01N2800/52 , Y02A50/412
摘要： In this application is described the expression and purification of a recombinant Plasmodium falciparum (FVO) MSP-1 42 . The method of the present invention produces a highly purified protein that retains folding and disulfide bridging of the native molecule. The recombinant MSP-1 42 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
-
公开(公告)号：EP2193196B1
公开(公告)日：2016-07-13
申请号：EP08834136.7
申请日：2008-09-26
发明人： LU, Genmin , PHILLIPS, David R. , ANDRE, Patrick , SINHA, Uma
CPC分类号： A61K38/4846 , A61K38/00 , A61K38/4826 , A61K38/4833 , A61K38/4853 , A61K39/00 , A61K47/60 , C07K14/435 , C12N9/6432 , C12Y304/21006
摘要： The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
-
公开(公告)号：EP2303793B1
公开(公告)日：2016-04-20
申请号：EP09746152.9
申请日：2009-05-08
CPC分类号： C04B18/162 , C04B2/005 , C04B2/106 , C04B7/24 , C04B28/36 , C04B2111/00724 , C04B2111/00732 , Y02P40/145 , Y02P40/18 , Y02P40/42 , Y02W30/95 , C04B20/023 , C04B14/42 , C04B40/0236
-
-
-
-
-
-
-
-
-
搜索结果
1521 条记录 (耗时 0.037 秒)
